Abstract
Purpose
Galectin-3, a member of the galectin family, is an endogenous β-galactoside-binding lectin. It plays an important role in the pathogenesis of multiple malignancies and its expression strongly also affects the outcomes of cancer patients. The objective of this study was to determine the clinical significance of the serum levels of galectin-3 in gastric cancer patients.
Material and methods
A total of 58 patients with diagnosis of gastric cancer were enrolled into this study. Serum galectin-3 concentrations were determined by the solid-phase sandwich ELISA method. Age- and sex-matched 30 healthy controls were included in the analysis.
Results
The median age at diagnosis was 59.5 years, range 32 to 82 years. There was no significant difference in the baseline serum galectin-3 levels between gastric cancer patients and healthy controls (p = 0.357). The older patients had elevated galectin-3 levels compared with younger ones (p = 0.02). The other known clinical variables including gender, site of lesion, histopathology, tumor size, lymph node involvement, and stage of disease were not correlated with serum galectin-3 concentrations (p > 0.05). Moreover, no relationship was shown between serum galectin-3 level and chemotherapy responsiveness (p = 0.36). Likewise, serum galectin-3 concentrations were not associated with prognosis on survival (p = 0.54).
Conclusion
Serum levels of galectin-3 have no diagnostic, predictive and prognostic roles in gastric cancer patients.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Gomes TS, Oshima CTF, Forones NM, Lima FDO, Riberio DA. Expression of galectin-3 in gastric adenocarcinoma. Indian J Med Res. 2014;140:69–76.
Okada K, Shimura T, Suehiro T, Mochiki E, Kuwano H. Reduced galectin-3 expression is an indicator of unfavorable prognosis in gastric cancer. Anticancer Res. 2006;26:1369–76.
Miyazaki J, Hokari R, Kato S, Tsuzuki Y, Kawaguchi A, Nagao S, et al. Increased expression of galectin-3 in primary gastric cancer and the metastatic lymph nodes. Oncol Rep. 2002;9:1307–12.
Baldus SE, Zirbes TK, Weingarten M, Fromm S, Glossman J, Hanisch FG, et al. Increased galectin-3 expression in gastric cancer: correlation with histopathological subtypes, galactosylated antigens and tumor cell proliferation. Tumor Biol. 2000;21:258–66.
Zhou JP, Yang ZL, Liu DC, Zhou JP. Expression of galectin-3 and Sambucus nigra agglutinin and their clinicopathological significance in benign and malignant lesions of stomach. Zhonghua Wei Chang Wai Ke Za Zhi. 2009;12:297–300.
Zhang XM, Yao GY, Zhang BY, Wang LL, Zhao M. Study on the expression and significance of galectin-3 and CDC25B mRNA in human gastric carcinoma. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2009;26:288–92.
Leal MF, Calcagno DQ, Chung J, De Freitas VM, Demachki S, Assumpçao PP, Chammas R, Burbano RR, Smith MC. Deregulated expression of annexin-A2 and galectin-3 is associated with metastasis in gastric cancer patients. Clin Exp Med 2014; July 18. doi:10.1007/s10238-014-0299-0
Kim SJ, Shin JY, Lee KD, Bae YK, Choi IJ, Park SH, et al. Galectin-3 facilitates cell motility in gastric cancer by up-regulating protease-activated receptor-1 (PAR-1) and matrix metalloproteinase-1 (MMP-1). PLoS One. 2011;6(9):e25103.
Cheong TC, Shin JY, Chun KH. Silencing of galectin-3 changes the gene expression and augments the sensitivity of gastric cancer cells to chemotherapeutic agents. Cancer Sci. 2010;101:94–102.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Funding
None
Conflict of interest
The authors declare that they have no conflict of interest.
Rights and permissions
About this article
Cite this article
Tas, F., Bilgin, E., Tastekin, D. et al. Clinical Significance of Serum Galectin-3 Levels in Gastric Cancer Patients. J Gastrointest Canc 47, 182–186 (2016). https://doi.org/10.1007/s12029-016-9817-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12029-016-9817-5